

Clinical Commissioning Policy

Benign skin lesions, removal

Category 2 Intervention - Only routinely commissioned when specific criteria are met -

Ref:	CMICB_Clin005
Version:	1
Purpose	This document is part of a suite of policies that the Integrated Care Board (ICB) uses to drive its commissioning of healthcare. Each policy in that suite is a separate public document in its own right but will be applied with reference to other policies in that suite.
Supersedes:	Previous Clinical Commissioning Group (CCG) Policy
Author (inc Job Title):	
Ratified by: (Name of responsible Committee)	ICB Board
Cross reference to other Policies/Guidance	
Date Ratified:	1 April 2023
Date Published and where (Intranet or Website):	1 April 2023 (Website)
Review date:	1 April 2026
Target audience:	All Cheshire & Merseyside ICB Staff and Provider organisations

This policy can only be considered valid when viewed via the ICB website or ICB staff intranet. If this document is printed into hard copy or saved to another location, you must check that the version number on your copy matches that of the one published.

Document control:		
Date:	Version Number:	Section and Description of Change
April 2023	1	Policy ratified by Cheshire & Merseyside ICB

1. Introduction

- 1.1 This policy relates to the commissioning of interventions which optimise clinical effectiveness and represent value for money.
- 1.2 This document is part of a suite of policies which the Integrated Care Board (ICB) uses to drive its commissioning of healthcare. Each policy is a separate public document in its own right but should be considered alongside all the other policies in the suite as well as the core principles outlined in Appendix 1.
- 1.3 At the time of publication, the evidence presented per procedure/treatment was the most current available.
- 1.4 This policy is based on NHS England's Evidence-Based Interventions (EBI) recommendations see link to programme below - accurate at the point of publication <https://www.aomrc.org.uk/ebi/clinicians/removal-of-benign-skin-lesions/>.

2. Purpose

- 2.1 This policy aims to ensure a common set of criteria for treatments and procedures across the region. This is intended to reduce variation of access to NHS services in different areas and allow fair and equitable treatment for all patients.

3. Summary of intervention

- 3.1 Removal of benign skin lesions means treating asymptomatic lumps, bumps or tags on the skin that are not suspicious of cancer. Treatment carries a small risk of infection, bleeding or scarring and is not usually offered by the NHS if it is just to improve appearance. In certain cases, treatment (surgical excision or cryotherapy) may be offered if certain criteria are met.
- 3.2 A patient with a skin or subcutaneous lesion that has features suspicious of malignancy must be treated or referred according to NICE skin cancer guidelines. This policy does not refer to pre-malignant lesions and other lesions with potential to cause harm.

4. Policy statement

- 4.1 Removal of *benign skin lesions** is only commissioned when at least ONE of the following criteria is met:
 - 4.1.1 The lesion is unavoidably and significantly traumatised on a regular basis with evidence of this causing regular bleeding or resulting in infections such that the patient requires 2 or more courses of antibiotics (oral or intravenous) per year
 - 4.1.2 There is repeated infection requiring 2 or more antibiotics per year
 - 4.1.3 The lesion bleeds in the course of normal everyday activity

* **Policy applies to the following benign lesions where there is diagnostic certainty:-**

benign moles (excluding large congenital naevi), solar comedones, corn/callous, dermatofibroma, lipomas, milia, molluscum contagiosum (non-genital), epidermoid & pilar cysts (sometimes incorrectly called sebaceous cysts), seborrhoeic keratoses (basal cell papillomata), skin tags (fibroepithelial polyps) including anal tags, spider naevi (telangiectasia), non-genital viral warts in immunocompetent patients, xanthelasmata or neurofibromata

- 4.1.4 The lesion causes regular pain
- 4.1.5 The lesion is obstructing an orifice or impairing field vision
- 4.1.6 The lesion significantly impacts on function e.g. restricts joint movement
- 4.1.7 The lesion causes pressure symptoms e.g. on nerve or tissue
- 4.1.8 If left untreated, more invasive intervention would be required for removal
- 4.1.9 Facial viral warts
- 4.1.10 Facial spider naevi in children causing significant psychological impact
- 4.1.11 Lipomas on the body > 5cms, or in a sub-facial position, with rapid growth and/or pain. These should be referred to Sarcoma clinic.

5. Exclusions

- 5.1 The following are outside the scope of this policy recommendation:
 - 5.1.1 Lesions that are suspicious of malignancy should be treated or referred according to NICE skin cancer guidelines.
 - 5.1.2 Any lesion where there is diagnostic uncertainty, pre-malignant lesions (actinic keratoses, Bowen disease) or lesions with pre-malignant potential should be referred or, where appropriate, treated in primary care.
 - 5.1.3 Removal of lesions other than those listed above.

6. Rationale

- 6.1 There is little evidence to suggest that removing benign skin lesions to improve appearance is beneficial. Risks of this procedure include bleeding, pain, infection and scarring. Though in certain specific cases as outlined by the criteria above, there are benefits for removing skin lesions, for example, avoidance of pain and allowing normal functioning.

7. Underpinning evidence

- 7.1 Higgins JC, Maher MH, Douglas MS. Diagnosing Common Benign Skin Am Fam Physician. 2015 Oct 1;92(7):601-7. PubMed PMID: 26447443.
- 7.2 Tan E, Levell NJ, Garioch JJ. The effect of a dermatology restricted-referral list upon the volume of referrals. Clin Exp Dermatol. 2007 Jan;32(1):114-5. PubMed PMID: 17305918

8. Force

- 8.1 This policy remains in force until it is superseded by a revised policy or by mandatory NICE guidance or other national directive relating to this intervention, or to alternative treatments for the same condition.

9. Coding

SQL code

```
WHEN left(der.Spell_Dominant_Procedure,4) IN  
( 'S063','S064','S065','S066','S067','S068','S069','S081','S082','S083'  
, 'S088','S089','S091','S092','S093','S094','S095','S098','S099','S101'  
, 'S102','S111','S112','D021','D022','D028','D029')  
AND apcs.der_diagnosis_all not like '%Z858%'  
AND APCS.Admission_Method not like ('2%')  
THEN 'F_skin_lesions'
```

Global cancer exclusion

```
APC  
WHERE 1=1  
-- Cancer Diagnosis Exclusion  
AND (apcs.der_diagnosis_all not like '%C[0-9][0-9]%'  
AND apcs.der_diagnosis_all not like '%D0%'  
AND apcs.der_diagnosis_all not like '%D3[789]%'  
AND apcs.der_diagnosis_all not like '%D4[012345678]%'  
OR apcs.der_diagnosis_all IS NULL)
```

10. Monitoring And Review

- 10.1 This policy may be subject to continued monitoring using a mix of the following approaches:
- Prior approval process
 - Post activity monitoring through routine data
 - Post activity monitoring through case note audits
- 10.2 This policy will be kept under regular review, to ensure that it reflects developments in the evidence base regarding effectiveness and value.

11. Quality and Equality Analysis

- 11.1 Quality and Equality Impact Analyses have been undertaken for this policy at the time of its review.

Appendix 1 - Core Objectives and Principles

Objectives

The main objective for having healthcare commissioning policies is to ensure that:

- Patients receive appropriate health treatments
- Treatments with no or a very limited evidence base are not used; and
- Treatments with minimal health gain are restricted.

Principles

This policy aims to ensure a common set of criteria for treatments and procedures across the region. This is intended to reduce variation of access to NHS services in different areas and allow fair and equitable treatment for all patients.

Commissioning decisions by ICB Commissioners are made in accordance with the commissioning principles set out as follows:

- Commissioners require clear evidence of clinical effectiveness before NHS resources are invested in the treatment.
- Commissioners require clear evidence of cost effectiveness before NHS resources are invested in the treatment.
- Commissioners will consider the extent to which the individual or patient group will gain a benefit from the treatment.
- Commissioners will balance the needs of an individual patient against the benefit which could be gained by alternative investment possibilities to meet the needs of the community.
- Commissioners will consider all relevant national standards and consider all proper and authoritative guidance.
- Where a treatment is approved Commissioners will respect patient choice as to where a treatment is delivered, in accordance with the 'NHS Choice' framework.
- Commissioning decisions will give 'due regard' to promote equality and uphold human rights. Decision making will follow robust procedures to ensure that decisions are fair and are made within legislative frameworks.

Core Eligibility Criteria

There are a number of circumstances where a patient may meet a 'core eligibility criterion' which means they are eligible to be referred for the procedures and treatments listed, regardless of whether they meet the criteria; or the procedure or treatment is not routinely commissioned.

These core clinical eligibility criteria are as follows:

- Any patient who needs 'urgent' treatment will always be treated.
- All NICE Technology Appraisals Guidance (TAG), for patients that meet all the eligible criteria listed in a NICE TAG will receive treatment.
- In cancer care (including but not limited to skin, head and neck, breast and sarcoma) any lesion that has features suspicious of malignancy, must be referred to an appropriate specialist for urgent assessment under the 2-week rule.
- NOTE: Funding for all solid and haematological cancers are now the responsibility of NHS England.
- Reconstructive surgery post cancer or trauma including burns.
- Congenital deformities: Operations on congenital anomalies of the face and skull are usually routinely commissioned by the NHS. Some conditions are considered highly specialised and are commissioned in the UK through the National Specialised Commissioning Advisory Group (NSCAG). As the incidence of some cranio-facial congenital anomalies is small and the treatment complex, specialised teams, working in designated centres and subject to national audit, should carry out such procedures.
- Tissue degenerative conditions requiring reconstruction and/or restoring function e.g. leg ulcers, dehisced surgical wounds, necrotising fasciitis.
- For patients wishing to undergo Gender reassignment, this is the responsibility of NHS England and patients should be referred to a Gender Identity Clinic (GIC) as outlined in the Interim NHS England Gender Dysphoria Protocol and Guideline 2013/14.

Cosmetic Surgery

Cosmetic surgery is often carried out to change a person's appearance to achieve what a person perceives to be a more desirable look.

Cosmetic surgery/treatments are regarded as procedures of low clinical priority and therefore not routinely commissioned by the ICB Commissioner.

A summary of Cosmetic Surgery is provided by NHS Choices. Weblink:
<http://www.nhs.uk/conditions/Cosmetic-surgery/Pages/Introduction.aspx> and
<http://www.nhs.uk/Conditions/Cosmetic-surgery/Pages/Procedures.aspx>

Diagnostic Procedures

Diagnostic procedures to be performed with the sole purpose of determining whether or not a restricted procedure is feasible should not be carried out unless the eligibility criteria are met, or approval has been given by the ICB or GP (as set out in the approval process of the patients responsible ICB) or as agreed by the IFR Panel as a clinically exceptional case.

Where a General Practitioner/Optometrlist/Dentist requests only an opinion the patient should not be placed on a waiting list or treated, but the opinion given and the patient returned to the care of the General Practitioner/Optometrlist/Dentist, in order for them to make a decision on future treatment.

Clinical Trials

The ICB will not fund continuation of treatment commenced as part of a clinical trial. This is in line with the Medicines for Human Use (Clinical Trials) Regulations 2004 and the Declaration of Helsinki which stipulates that the responsibility for ensuring a clear exit strategy from a trial, and that those benefiting from treatment will have ongoing access to it, lies with those conducting the trial. This responsibility lies with the trial initiators indefinitely.

Clinical Exceptionality

If any patients are excluded from this policy, for whatever reason, the clinician has the option to make an application for clinical exceptionality. However, the clinician must make a robust case to the Panel to confirm their patient is distinct from all the other patients who might be excluded from the designated policy.

The ICB will consider clinical exceptions to this policy in accordance with the Individual Funding Request (IFR) Governance Framework consisting of: IFR Decision Making Policy; and IFR Management Policy.